/ACLX
ACLX Stock - Arcellx, Inc.
Healthcare|BiotechnologyNASDAQ
$63.96-0.27%
$0.17 (-0.27%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.25
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+80.8%upside
Target: $115.64
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACLX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$63.32 – $64.60
TARGET (TP)$115.67
STOP LOSS$58.84
RISK/REWARD1:10.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.34
52W High$94.07
52W Low$47.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $107.94M | $110.32M | N/A | N/A | N/A |
| Gross Profit | $102.75M | $110.32M | $-2,224,000 | N/A | N/A |
| Gross Margin | 95.2% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-137,571,000 | $-89,880,000 | $-191,259,000 | $-65,018,000 | $-32,095,999 |
| Net Income | $-107,348,000 | $-70,690,000 | $-188,679,000 | $-64,969,000 | $-32,095,000 |
| Net Margin | -99.5% | -64.1% | N/A | N/A | N/A |
| EPS | $-2.00 | $-1.47 | $-4.28 | $-1.94 | $-1.47 |
Company Overview
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
15
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
15 Bullish0 Neutral/Bearish
Price Targets
$63
Average Target
↓ 1.5% Downside
Now
$31
Low
$63
Average
$129
High
Based on 16 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| October 16th 2025 | Stifel | Initiation | Buy | $129 |
| June 17th 2025 | Citigroup | Initiation | Buy | $110 |
| October 8th 2024 | Redburn Atlantic | Initiation | Buy | $109 |
| September 3rd 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| May 31st 2024 | Piper Sandler | Initiation | Overweight | $70 |
| March 7th 2024 | Morgan Stanley | Initiation | Overweight | $81 |
| January 4th 2024 | Needham | Reiterated | Buy | $71← $65 |
| December 19th 2023 | Scotiabank | Initiation | Sector Outperform | $66 |
| October 30th 2023 | TD Cowen | Initiation | Outperform | - |
| October 17th 2023 | UBS | Initiation | Buy | $52 |
| May 18th 2023 | Truist | Initiation | Buy | $60 |
| April 14th 2023 | Robert W. Baird | Initiation | Outperform | $39 |
| March 14th 2023 | Stifel | Initiation | Buy | $43 |
| February 13th 2023 | H.C. Wainwright | Initiation | Buy | $42 |
Earnings History & Surprises
ACLXBeat Rate
56%
Last 16 quarters
Avg Surprise
+2.4%
EPS vs Estimate
Beats / Misses
9/7
Last 12 quarters
Latest EPS
$-0.99
Q4 2025
EPS Surprise History
Q1 24
+168.9%
$0.42vs$-0.61
Q2 24
+72.5%
$-0.14vs$-0.51
Q3 24
+5.6%
$-0.51vs$-0.54
Q4 24
+11.1%
$-0.48vs$-0.54
Q1 25
-38.1%
$-0.87vs$-0.63
Q2 25
-34.5%
$-1.13vs$-0.84
Q3 25
+8.7%
$-0.94vs$-1.03
Q4 25
-3.1%
$-0.99vs$-0.96
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 17, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.01 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.96 | $-0.99 | -3.1% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.03 | $-0.94 | +8.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.84 | $-1.13 | -34.5% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.63 | $-0.87 | -38.1% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.54 | $-0.48 | +11.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.54 | $-0.51 | +5.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.51 | $-0.14 | +72.5% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.61 | $0.42 | +168.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.56 | $-0.81 | -44.6% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.68 | $-0.50 | +26.5% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $2.52 | $-0.58 | -123.0% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.71 | $-0.76 | -7.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.93 | $-0.68 | +26.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-1.20 | $-0.88 | +26.7% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.95 | $-1.56 | -64.2% | ✗ MISS |
Q1 2022 | Feb 7, 2022 | $-0.66 | $-0.62 | +6.6% | ✓ BEAT |
Q1 2022 | Jan 14, 2022 | — | $-0.78 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.73 | — | — |
Latest News
Canaccord Genuity Maintains Buy on Arcellx, Maintains $130 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 05:50 PM•Also:
Arcellx shares are trading higher after the company reported that Anito-Cel demonstrated a 96% overall response rate and 74% complete/sCR rate in the iMMagine-1 trial for relapsed/refractory multiple myeloma.
📈 PositiveBenzinga•Dec 8, 2025, 01:55 PM
Needham Reiterates Buy on Arcellx, Maintains $105 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 10:39 AM
Reported Saturday, Anito-Cel Demonstrates 96% ORR And 74% CR/sCR In iMMagine-1 Relapsed/Refractory Multiple Myeloma, Supporting Planned 2026 Commercial Launch
📈 PositiveBenzinga•Dec 8, 2025, 08:47 AM
Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma
📉 NegativeSeeking Alpha•Nov 24, 2025, 10:33 PM
Wolfe Research Initiates Coverage On Arcellx with Peer Perform Rating
➖ NeutralBenzinga•Nov 18, 2025, 05:17 PM
Arcellx Q3 EPS $(0.99) Beats $(1.03) Estimate, Sales $4.949M Miss $9.639M Estimate
➖ NeutralBenzinga•Nov 5, 2025, 10:29 PM
Arcellx To Share Two Presentations Including Updated Clinical Data From iMMagine-1, Phase 2 Pivotal Study Of Anitocabtagene Autoleucel In Patients With RRMM, At ASH 2025
➖ NeutralBenzinga•Nov 3, 2025, 02:04 PM
Canaccord Genuity Maintains Buy on Arcellx, Raises Price Target to $130
📈 PositiveBenzinga•Nov 3, 2025, 01:25 PM•Also:
Stifel Reinstates Buy on Arcellx, Announces $129 Price Target
📈 PositiveBenzinga•Oct 16, 2025, 01:52 PM•Also:
Cantor Fitzgerald Assumes Arcellx at Neutral, Announces Price Target of $88
➖ NeutralBenzinga•Oct 9, 2025, 01:10 PM
Frequently Asked Questions about ACLX
What is ACLX's current stock price?
Arcellx, Inc. (ACLX) is currently trading at $63.96 per share. The stock has moved -0.27% today.
What is the analyst price target for ACLX?
The average analyst price target for ACLX is $115.67, based on 1 analyst.
What sector is Arcellx, Inc. in?
Arcellx, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACLX's market cap?
Arcellx, Inc. has a market capitalization of $3.54 billion, making it a mid-cap company.
Does ACLX pay dividends?
No, Arcellx, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
ALKS
Alkermes plc
$28.45
Mkt Cap: $4.7B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
PTGX
Protagonist Therapeutics, Inc.
$86.05
Mkt Cap: $5.4B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to ACLX for comparison